Ainos, Inc. (NASDAQ:AIMD) Sees Large Decline in Short Interest

Ainos, Inc. (NASDAQ:AIMD) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 72,700 shares, a decline of 7.9% from the March 31st total of 78,900 shares. Based on an average trading volume of 1,350,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.8% of the company’s stock are short sold.

Ainos Price Performance

Shares of AIMD opened at $1.04 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.85 and a quick ratio of 1.72. The company has a market capitalization of $6.39 million, a price-to-earnings ratio of -0.41 and a beta of 1.44. The business’s 50-day moving average is $1.14 and its 200-day moving average is $1.90. Ainos has a fifty-two week low of $0.79 and a fifty-two week high of $6.10.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.